Fertility | Jotup

eIVF and Rectangle Health Partner to Streamline Payment Processing and Enhance the Patient Experience in Fertility Care

Retrieved on:

Tuesday, March 19, 2024

Software, Practice Management, Payments, Finance, Health, Data Management, Professional Services, Technology, Financial management, Practice management software, Partnership, Patient, SVP, History, Fertility, Workflow, ASC, Payment

This strategic collaboration brings together the strengths of both companies to offer an enhanced financial management experience for fertility clinics and their patients.

Key Points:

This strategic collaboration brings together the strengths of both companies to offer an enhanced financial management experience for fertility clinics and their patients.
This partnership simplifies the financial interactions between clinics and patients, helps to ease cost-related barriers to care, and improves the overall patient experience.
"Our integration with Rectangle Health marks another significant step in our ongoing quest to enhance eIVF’s unified platform through innovative partnerships,” stated Nimesh Shah, PracticeHwy CEO.
Brian Doyle, SVP of Sales and Technology Partnerships for Rectangle Health shares, "We are excited to partner with PracticeHwy to support the increasing need for fertility and reproductive care.

Meitheal Pharmaceuticals Announces Recent Business Progress Reinforcing Commitment to Sustainable Generics Development

Retrieved on:

Tuesday, March 19, 2024

As we prepare to launch multiple new products in 2024, we are intently focused on expediting delivery of medicines in short supply,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals.

Key Points:

As we prepare to launch multiple new products in 2024, we are intently focused on expediting delivery of medicines in short supply,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals.
As of March 1, 2024, both the U.S. Food and Drug Administration (FDA) and the American Society of Health-System Pharmacists (ASHP) websites list multiple presentations of Bupivacaine Hydrochloride Injection on drug shortage.
These approved lines add over 200 million units of capacity for vial and cartridge products that support current and future demand for generic injectables.
These lines are expected to produce commercial products that will have an impact on drug shortages beginning in the second half of 2024.

Reproductive Medicine Associates Opens New State-of-the-Art Fertility Center and IVF Lab in Bellevue, Expanding Access to Fertility Care in Washington State

Retrieved on:

Wednesday, March 13, 2024

Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, announced the opening of its new state-of-the-art fertility center and in vitro fertilization lab (IVF) in Bellevue.

Key Points:

Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, announced the opening of its new state-of-the-art fertility center and in vitro fertilization lab (IVF) in Bellevue.
The clinic is RMA’s second location in Washington state, after Seattle, and adds to an extensive network of more than sixty RMA clinics across the United States.
“We’re committed to expanding access to cutting-edge fertility care for the roughly 1 in 5 Americans who struggle with infertility,” said Lynn Mason, CEO of IVI RMA America.
The center will also offer family planning resources and options for LGBTQ+ individuals and fertility preservation treatments for those individuals with autoimmune diseases or cancer diagnoses.

As Opill Enhances Women's Reproductive Choices Dr. Mary Jane Minkin Highlights Key Differences Between the Progesterone-Only Opill and Traditional Estrogen-Based Contraceptives “The Pill”

Retrieved on:

Monday, March 11, 2024

Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.

Key Points:

Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.
"Education is key at this juncture to prevent an increase in unintended pregnancies in the coming months.
The Opill, significantly differs from the traditional birth control pill in that it is less effective at preventing ovulation when pills are missed or skipped for any reason.
The availability of the Opill OTC, or progesterone-only pill, is wonderful news for those women unable to take estrogen or 'The Pill.'

NewGenIvf and A SPAC I Announce Closing of Business Combination

Retrieved on:

Wednesday, April 3, 2024

ASCA, New Generation Pictures, Growth, CFO, Business, Acquisition, Fertility, Business analyst, Ogier the Dane

NEW YORK, April 3, 2024 /PRNewswire/ -- NewGenIvf Limited ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, and A SPAC I Acquisition Corp. (NASDAQ: ASCA) ("A SPAC I"), a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The combined company will be named "NewGenIvf Group Limited" ("NewGenIvf Group") and its shares and warrants are expected to begin trading on the Nasdaq Capital Market under the tickers "NIVF", and "NIVFW", respectively, on April 4, 2024.

Key Points:

Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen commented, "We are thrilled to announce our upcoming debut on the Nasdaq as we complete our business combination with A SPAC I.
Demand for fertility services is growing across Asia, and we are uniquely positioned to take advantage of this emerging opportunity.
Claudius Tsang, CEO, CFO and Chairman of A SPAC I, commented, "We are excited to complete the Business Combination, and to see what NewGen will accomplish in this new chapter of its story.
Loeb & Loeb LLP and Ogier served as legal counsel to A SPAC I in connection with the Transaction.

Coast Guard Mutual Assistance (CGMA) and WIN Join Forces to Support Coast Guard Families in Their Family-Building Journey

Retrieved on:

Wednesday, April 3, 2024

TRICARE, RET, Infertility, Partnership, WIN, Female, Fertility, Coast guard, Woman, USCG, CGMA, Coast Guard Mutual Assistance, Family, Birth control

GREENWICH, Conn., April 3, 2024 /PRNewswire/ -- WIN, the nation's leading family-building and family well-being benefit company, is proud to announce its collaboration with Coast Guard Mutual Assistance (CGMA) to provide comprehensive fertility benefit management services for Coast Guard members. The donated services offered include 24/7 clinical guidance through WIN Nurse Care Advocates, reproductive behavioral support, access to the WIN highly credentialed qualified network of medical and pharmacy providers and on-demand clinical support and resources through the WINFamily app—wherever their duties take them, along with available discounts, and guided counseling on family-building options.

Key Points:

The CGMA-WIN initiative seeks to address these challenges by offering comprehensive support tailored to the needs of Coast Guard service members and their families.
"We understand the challenges that military families face and are committed to supporting Coast Guard members on their journey to parenthood.
Through this partnership, we aim to provide comprehensive and accessible resources that empower Coast Guard families to build their families."
"We are thrilled to offer WIN's support to our Coast Guard community's family-building aspirations," said RADM Cari B. Thomas, USCG (Ret), CEO of Coast Guard Mutual Assistance.

Gameto Announces Patient Experience Data Demonstrating Investigational In Vitro Maturation Solution Well Tolerated with Higher Patient Satisfaction Rates than Conventional Fertility Stimulation

Retrieved on:

Tuesday, April 2, 2024

NEW YORK, April 2, 2024 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, today announced encouraging new findings from a study evaluating how minimal controlled ovarian stimulation (COS) in combination with Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSC-IVM) to mature eggs outside of the body, affected patients' egg retrieval experiences when compared to conventional stimulation. The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).

Key Points:

The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).
"We are encouraged by these and previously published efficacy data which demonstrate that combining minimal hormonal stimulation with our investigational in vitro maturation solution may help women navigating fertility treatments avoid many of the common side effects associated with the conventional IVF hormone protocol.
Gameto's goal in developing Fertilo is to make fertility treatments more convenient, safer, and accessible for a wider patient population.
[1],[2] In contrast, the participants in this analysis who underwent minimal ovarian stimulation cycles followed by OSC-IVM yielded no incidence of OHSS.

The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab

Retrieved on:

Friday, March 29, 2024

Genetic testing, Partnership, Physician, Patient, Fertility, Insurance, Inception, FDA, LH, Genetic counseling

HOUSTON, March 29, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp (NYSE: LH), a global leader of innovative diagnostic and biopharma laboratory services, to serve as its Preferred Genetic Carrier Screening Lab.

Key Points:

The expansion of this partnership delivers another level of genetic carrier screening services to Prelude patients, including in-office phlebotomists and patient service centers.
Additionally, Labcorp offers comprehensive genetic counseling, services for provider questions, and complimentary review of carrier screening results for patients.
To improve financial access to genetic carrier screening for the U.S. patient population, Labcorp is contracted with many insurance companies.
"Prelude is excited to offer our patients greater access to best-in-class genetic carrier screening," says Lauri Black, Certified Genetic Counselor and Director of Genetic Services at Inception.

CYNTHIA BAILEY PARTNERS WITH KINDRA TO RAISE AWARENESS ABOUT VAGINAL HEALTH DURING MENOPAUSE

Retrieved on:

Thursday, March 28, 2024

Health, Puberty, Weight gain, Research, Menopause, Fertility, Dry, Woman, Skin, Irritation, Personal lubricant, Bailey, Fatigue, Collection, Human, Birth control

NEW YORK, March 28, 2024 /PRNewswire/ -- Kindra , the menopause and vaginal health brand, announces actress and model Cynthia Bailey as brand ambassador to raise awareness for menopause and vaginal wellness by heightening the conversation around the sexual health of women at every age.

Key Points:

NEW YORK, March 28, 2024 /PRNewswire/ -- Kindra , the menopause and vaginal health brand, announces actress and model Cynthia Bailey as brand ambassador to raise awareness for menopause and vaginal wellness by heightening the conversation around the sexual health of women at every age.
As long-term champions for breaking down stigmas around women's health, Bailey and Kindra share a vision to increase conversations around the vast spectrum of needs as it relates to a woman's sexual health.
Vaginas have no expiration date, and Kindra's array of care, solutions, and services cater to the needs of vaginal health and sexual wellness.
Whether it's embracing the transitions of menopause, tackling contraceptive dryness, or navigating postpartum challenges, Kindra provides women and their healthcare practitioners with clinically-backed, trusted solutions and educational resources on vaginal health and sexual wellness.

Family Source Consultants Celebrates Michigan Legislature Passing Landmark Fertility Health Care Act (House Bill 5207) to Legalize Surrogacy Arrangements

Retrieved on:

Wednesday, March 27, 2024

Michigan Legislature, Infertility, Child, Fertility, Family, Organization, House, Woman, Heart, Consultant, Dream, Reproductive rights, Parent, Legislation, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Family Source Consultants Celebrates Michigan Legislature Passing Landmark Fertility Health Care Act (House Bill 5207) to Legalize Surrogacy Arrangements.

Key Points:

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Family Source Consultants Celebrates Michigan Legislature Passing Landmark Fertility Health Care Act (House Bill 5207) to Legalize Surrogacy Arrangements.
Family Source Consultants, a leading third-party reproduction agency that specializes in matching and facilitating surrogacy and egg donation arrangements, praises the Michigan Legislature for taking a historic step forward in reproductive rights by passing the Fertility Health Care Act ( House Bill 5207 ).
This groundbreaking legislation legalizes and regulates surrogacy arrangements in the state of Michigan providing transparency and protection for all parties involved in a surrogacy arrangement.
By providing a legal framework for surrogacy, the Fertility Health Care Act aims to promote fairness, transparency, and ethical practices within the surrogacy process.